SurVaxM was created in a lab at Roswell Park by Robert Fenstermaker, MD, Chair of Neurosurgery and Michael Ciesielski, PhD, Assistant Professor of Neurosurgery. Dr. Fenstermaker is the Principal Investigator of the nationwide randomized trial and Dr. Ciesielski is CEO of MimiVax, the corporate which now produces SurVaxM. Their work has been passionately supported by donor funding for the previous 10 years, proving instrumental in bringing this new therapy to the place it’s right this moment.
Right here’s the way it all went down:
